NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

Neurotrope Inc (NASDAQ:NTRP) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. View Neurotrope's Earnings History.

Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope.

2 analysts have issued 1-year price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $16.00. On average, they anticipate Neurotrope's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 580.0% from the stock's current price. View Analyst Price Targets for Neurotrope.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

News headlines about NTRP stock have trended extremely negative on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurotrope earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Neurotrope.

Neurotrope saw a decline in short interest in December. As of December 31st, there was short interest totalling 536,700 shares, a decline of 7.6% from the December 15th total of 580,600 shares. Based on an average daily volume of 272,500 shares, the short-interest ratio is currently 2.0 days. Approximately 5.5% of the shares of the stock are sold short. View Neurotrope's Current Options Chain.

Some companies that are related to Neurotrope include Eyenovia (EYEN), NewLink Genetics (NLNK), CTI BioPharma (CTIC), CNS Pharmaceuticals (CNSP), Tiziana Life Sciences (TLSA), Chembio Diagnostics (CEMI), AgeX Therapeutics (AGE), Aridis Pharmaceuticals (ARDS), Entasis Therapeutics (ETTX), Aclaris Therapeutics (ACRS), Sunesis Pharmaceuticals (SNSS), Kezar Life Sciences (KZR), Acasti Pharma (ACST), Soligenix (SNGX) and Alpine Immune Sciences (ALPN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Pieris Pharmaceuticals (PIRS), Canopy Growth (CGC), Innovate Biopharmaceuticals (INNT), Intel (INTC), Iovance Biotherapeutics (IOVA) and Adamis Pharmaceuticals (ADMP).

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRP stock can currently be purchased for approximately $1.25.

Neurotrope has a market capitalization of $16.34 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

The official website for Neurotrope is http://www.neurotropebioscience.com/.

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]